MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Total Current Assets
All assets expected to be converted to cash or used up within one year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 233.0% from a year ago
Total current assets stood at $327.23M at the end of Q1 FY2026, up 233.0% from a year earlier and up 0.8% from the prior quarter. Over 3 fiscal years it compounded at +116.4% a year.
Context
- Total current assets amounted to 78.1% of total assets at the end of Q1 FY2026, down 9.9 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +233.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 324.67M USD
- Year-over-year change
- +183.3%
- 3-year CAGR
- +116.4%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 324.67M | +183.3% |
| FY2024 | 2024-12-31 | 114.6M | +37.1% |
| FY2023 | 2023-12-31 | 83.6M | +161.0% |
| FY2022 | 2022-12-31 | 32.03M | — |
Total Current Assets vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 total current assets of $327.23M is the 5th highest of the 11 companies compared; the peer median is $270.68M.
- Its year-over-year change of +233.0% is the 5th highest of 11, against a peer median of +124.2%.
- Total current assets amounts to 78.1% of total assets for MPLT, versus a peer median of 97.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $79.73B | +512730.9% | +27.4% | 83.9% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $1.05B | +387.3% | +42.1% | 97.9% |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $484.7M | +66.6% | +151.7% | 97.4% |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $389.07M | +2532.3% | +143.0% | 98.9% |
| Mar 2026 | $327.23M | +233.0% | +116.4% | 78.1% | |
| Mar 2026 | $272.23M | -7.6% | +19.3% | 98.9% | |
| Mar 2026 | $269.13M | +64.6% | +53.4% | 97.4% | |
| Mar 2026 | $229.97M | +181.9% | +33.9% | 82.6% | |
| Mar 2026 | $160.15M | +248.7% | -11.7% | 71.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $153.43M | -39.8% | -21.1% | 99.7% |
| Dec 2025 | $132.99M | +7.2% | -12.1% | 100.0% | |
| Peer median (excluding MPLT) | $270.68M | +124.2% | +30.7% | 97.7% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.